Claims for Patent: 5,945,397

Summary for Patent: 5,945,397

Title:	Purified p75 (type II) tumor necrosis factor receptor polypeptides
Abstract:	Human tumor necrosis factor receptor proteins having the of amino acids 1-235 are disclosed in SEQ ID NO:2. TNF receptor deletion variants having the sequence of amino acids 1-185 or 1-163 of SEQ ID NO:2 also display TNF bing activity. Murine TNF receptor proteins are also disclosed in SEQ ID NO:4 and are capable of binding TNF.
Inventor(s):	Smith; Craig A. (Seattle, WA), Goodwin; Raymond G. (Seattle, WA), Beckmann; M. Patricia (Poulsbo, WA)
Assignee:	Immunex Corporation (Seattle, WA)
Application Number:	08/650,000
Patent Claims:	1. A composition consisting essentially of a protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein is capable of binding TNF. 2. The composition according to claim 1, wherein said protein comprises amino acids 1-163 of SEQ ID NO:2. 3. The composition to claim 1, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 4. The composition according to claim 1, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 5. A composition consisting essentially of a protein selected from the group consisting of: (a) a polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2; (b) a polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO:4; and (c) a polypeptide identical to the polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said protein is capable of binding TNF. 6. A pharmaceutical composition comprising a protein according to claim 1, 2, 3, 4 or 5, and a pharmaceutically acceptable diluent or carrier. 7. A protein free of conspecific proteins comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein is capable of binding TNF. 8. The protein according to claim 7, wherein said protein comprises amino acids 1-163 of SEQ ID NO:2. 9. The protein according to claim 8, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 10. The protein according to claim 9, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 11. An isolated and purified protein comprising a polypeptide identical to a polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2 or identical to a polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO:4, except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said protein is capable of binding TNF. 12. A pharmaceutical composition comprising a protein according to claim 7, 8, 9 10 or 11, and a pharmaceutically acceptable diluent or carrier. 13. An isolated and purified soluble TNF receptor protein comprising a sequence of amino acids-selected from the group consisting of from amino acid 1 to about amino acid 163 of SEQ ID NO:2 and from about amino acid 1 to about amino acid 233 of SEQ ID NO:4, wherein said soluble TNF receptor protein is capable of binding TNF protein. 14. The isolated and purified soluble TNF receptor protein according to claim 13, wherein said soluble TNF receptor protein comprises from amino acid 1 to about amino acid 163 of SEQ ID NO:2. 15. The isolated and purified soluble TNF receptor protein according to claim 13, wherein said soluble TNF receptor protein comprises from amino acid 1 to about amino acid 185 of SEQ ID NO:2. 16. An isolated and purified soluble TNF receptor protein comprising from about amino acid 1 to about amino acid 235 of SEQ ID NO:2. 17. An isolated and purified soluble TNF receptor protein selected from the group consisting of: (a) a TNF receptor polypeptide having a sequence of amino acids comprising from about amino acid 1 to about amino acid 163 of SEQ ID NO:2; (b) a TNF receptor polypeptide having a sequence of amino acids comprising from about amino acid 1 to about amino acid 233 of SEQ ID NO:4; and (c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said soluble TNF receptor protein is capable of binding TNF. 18. An isolated and purified soluble TNF receptor protein selected from the group consisting of: (a) a TNF receptor polypeptide having a sequence of amino acids comprising from about amino acid 1 to about amino acid 235 of SEQ ID NO:2; and (b) a TNF receptor polypeptide identical to the TNF receptor polypeptide of (a) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said soluble TNF receptor protein is capable of binding TNF. 19. A pharmaceutical composition comprising a soluble TNF receptor protein according to claim 13, 14, 15, 16, 17 and 18 a pharmaceutically acceptable diluent or carrier. 20. An isolated and purified soluble TNF receptor protein comprising a sequence of amino acids selected from the group consisting of from amino acid 1 to amino acid 163 of SEQ ID NO:2 and from amino acid 1 to amino acid 233 of SEQ ID NO:4, wherein said soluble TNF receptor protein is capable of binding TNF protein. 21. The isolated and purified soluble TNF receptor protein according to claim 20, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 163 of SEQ ID NO:2. 22. The isolated and purified soluble TNF receptor protein according to claim 20, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 185 of SEQ ID NO:2. 23. The isolated and purified soluble TNF receptor protein according to claim 20, wherein said soluble TNF receptor protein comprises from amino acid 1 to amino acid 235 of SEQ ID NO:2. 24. An isolated and purified soluble TNF receptor protein selected from the group consisting of: (a) a TNF receptor polypeptide having a sequence of amino acids comprising from amino acid 1 to amino acid 163 of SEQ ID NO:2; (b) a TNF receptor polypeptide having a sequence of amino acids comprising from amino acid 1 to amino acid 233 of SEQ ID NO:4; and (c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said soluble TNF receptor protein is capable of binding TNF. 25. A pharmaceutical composition comprising a soluble TNF receptor protein according to claim 20, 21, 22, 23 or 24, and a pharmaceutically acceptable diluent or carrier. 26. A isolated and purified protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein lacks amino acids 236-265 of SEQ ID NO:2 and amino acids 234-265 of SEQ ID NO:4, respectively, and wherein said protein is capable of binding TNF. 27. The isolated and purified protein according to claim 26, wherein said protein comprises amino acids 1-163 of SEQ ID NO:2. 28. The isolated and purified protein according to claim 26, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 29. The isolated and purified protein, according to claim 26, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 30. An isolated and purified protein selected from the group consisting of: (a) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2, wherein said polypeptide lacks amino acids 236-265 of SEQ ID NO:2; (b) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO4, wherein said polypeptide lacks amino acids 234-265 of SEQ ID NO:4; and (c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said protein is capable of binding TNF. 31. A pharmaceutical composition comprising a protein according to claim 26, 27, 28, 29 or 30, and a pharmaceutically acceptable diluent or carrier. 32. An isolated and purified protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein lacks a functional transmembrane region, and wherein said protein is capable of binding TNF. 33. The isolated and purified protein according to claim 32, wherein said protein comprises amino acids 1-163 of SEQ ID NO:2. 34. The isolated and purified protein according to claim 32, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 35. The isolated and purified protein, according to claim 32, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 36. An isolated and purified protein selected from the group consisting of: (a) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2; (b) a TNF receptor polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO:4; and (c) a TNF receptor polypeptide identical to the TNF receptor polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said protein lacks a functional transmembrane region; and wherein said protein is capable of binding TNF. 37. A pharmaceutical composition comprising a protein according to claim 32, 33, 34, 35 or 36, and a pharmaceutically acceptable diluent or carrier. 38. A recombinant microbial protein comprising a sequence of amino acids selected from the group consisting of amino acids 1-163 of SEQ ID NO:2 and amino acids 1-233 of SEQ ID NO:4, wherein said protein is capable of binding TNF. 39. The recombinant microbial protein according to claim 38, wherein said protein comprises amino acids 1-163 of SEQ ID NO:2. 40. The recombinant microbial protein to claim 39, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 41. The recombinant microbial protein according to claim 31, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 42. A recombinant microbial protein selected from the group consisting of: (a) a polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2; (b) a polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO:4; and (c) a polypeptide identical to the polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, wherein said protein is capable of binding TNF protein. 43. A pharmaceutical composition comprising a recombinant microbial protein according to claim 38, 39, 40, 41 or 42, and a pharmaceutically acceptable diluent or carrier. 44. A protein produced by a process comprising culturing non-human host cells which have been modified by the introduction of a nucleic acid molecule encoding a protein comprising the sequence of amino acids 1-163 of SEQ ID NO:2 under conditions suitable to effect expression of the introduced nucleic acid molecule; wherein said protein is capable of binding TNF protein. 45. The protein to claim 44, wherein said protein comprises amino acids 1-185 of SEQ ID NO:2. 46. The protein according to claim 44, wherein said protein comprises amino acids 1-235 of SEQ ID NO:2. 47. A protein produced by a process comprising culturing non-human host cells which have been modified by the introduction of a nucleic acid molecule encoding a protein selected from the group consisting of: (a) a polypeptide having a sequence of amino acids comprising amino acids 1-163 of SEQ ID NO:2; (b) a polypeptide having a sequence of amino acids comprising amino acids 1-233 of SEQ ID NO:4; and (c) a polypeptide identical to the polypeptides of (a) or (b) except for one or more modification(s) to the sequence of amino acids selected from the group consisting of: (i) inactivated N-linked glycosylation sites; (ii) altered KEX2 protease cleavage sites; and (iii) substitution or deletion of cysteine residues, under conditions suitable to effect expression of the introduced nucleic acid molecule; and wherein said protein is capable of binding TNF. 48. The protein according to claims 44, 45, 46 or 47, wherein said non-human host cells are selected from the group consisting of L cell, C127 cells, 3T3 cells, CHO cells, BHK cells and COS-7 cells. 49. The protein according to claims 44, 45, 46 or 47, wherein said non-human host cells are CHO cells. 50. A pharmaceutical composition comprising a protein according to claim 44, 45, 46 or 47, and a pharmaceutically acceptable diluent or carrier. 51. A pharmaceutical composition comprising a protein according to claim 48, and a pharmaceutically acceptable diluent or carrier. 52. A pharmaceutical composition comprising a protein according to claim 49, and a pharmaceutically acceptable diluent or carrier.

Details for Patent 5,945,397

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	November 02, 1998	5,945,397	2009-09-11
Immunex Corporation	ENBREL	etanercept	For Injection	103795	May 27, 1999	5,945,397	2009-09-11
Immunex Corporation	ENBREL	etanercept	Injection	103795	September 27, 2004	5,945,397	2009-09-11

International Patent Family for US Patent 5,945,397

Country	Patent Number	Estimated Expiration
South Africa	907072
World Intellectual Property Organization (WIPO)	9406476
World Intellectual Property Organization (WIPO)	9319777